Drug Profile
IC 100 - InflamaCORE/ZyVersa Therapeutics
Alternative Names: IC 100-01; IC 100-02; IC 100-03; IC 100-04; IC 100-05; IC 100-06; IC100 - ZyVersa Therapeutics/InflamaCORE; ICCN-100; Inflammasome ASC Inhibitor IC-100Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator InflamaCORE; University of Miami
- Developer InflamaCORE; ZyVersa Therapeutics
- Class Anti-inflammatories; Antidementias; Hepatoprotectants; Monoclonal antibodies; Urologics; Vascular disorder therapies
- Mechanism of Action Inflammasome inhibitors; PYCARD protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Adult respiratory distress syndrome; Alzheimer's disease; Atherosclerosis; Metabolic disorders; Neurodegenerative disorders
- Research Autoimmune disorders
- No development reported Acute lung injury; Brain injuries; Diabetic nephropathies; Lupus nephritis; Multiple sclerosis; Non-alcoholic steatohepatitis; Spinal cord injuries; Stroke
Most Recent Events
- 25 Mar 2024 ZyVersa Therapeutics plans preclinical studies for Metabolic disorders in Q2-2024
- 28 Feb 2024 Preclinical trials in Metabolic disorders in USA (Parenteral) prior to February 2024
- 28 Feb 2024 Pharmacodynamics data from preclinical trial in Metabolic disorders released by ZyVersa Therapeutics